Journals / Journal of Experimental and Clinical Medicine / 2023 / Cilt: 40 Sayı: 3

The efficacy of propolis extracts as a food supplement in patients with COVID-19

Pages
443–447
Publication Date
2023-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The use of propolis as a food supplement has been shown to have a range of health benefits, and the addition of it to the treatment regimen for COVID-19 may help to reduce the severity and duration of symptoms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Propolis is a natural immunomodulator with anticancer, antiviral, and anti-inflammatory effects.
📊
Key Findings & Data:Propolis may be considered an agent in the supportive treatment of COVID-19.
💡
Conclusion & Impact:The use of propolis as a food supplement has been shown to have a range of health benefits, and the addition of it to the treatment regimen for COVID-19 may help to reduce the severity and duration of symptoms.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:caffeic acid · coronavirus · COVID-19

Abstract

Propolis is a natural immunomodulator with anticancer, antiviral, and anti-inflammatory effects. Propolis may be considered an agent in the supportive treatment of COVID-19. Propolis is known for its wide range of pharmacological properties, with many studies finding it effective in both the prevention and treatment of a variety of conditions. Forty-five patients who were hospitalized in our hospital and did not need intensive care were divided into groups of 15. The patients were receiving the standard COVID-19 treatment protocol. In the randomized, controlled study, one group of patients received 2 ml of water extract of propolis (WEP) (50 mg/ml) orally three times a day for one week, while another group received 1 ml of olive oily extract of propolis (64 mg/ml) plus 1 ml of olive oily Perga extract (120 mg/ml) (OEP). Hospital discharge times and changes in biochemical parameters were used as indicators of recovery. The WEP and OEP groups were found to have statistically significantly better D-dimer, CRP, and WBC results than the control group when the improvement in parameters between the groups were compared. Significantly different hospital discharge times in groups 1 and 2 were found compared to the control group. The addition of propolis to the treatment as a food supplement has a positive effect on the recovery of patients with COVID-19 and may shorten the treatment time. The use of propolis as a food supplement has been shown to have a range of health benefits, and the addition of it to the treatment regimen for COVID-19 may help to reduce the severity and duration of symptoms.

🔖

Cite This Article

KULAKSIZ, B. D., DEĞER, O., ATAYOĞLU, A. T., SEVİL, E., KULAKSIZ, D. (2023). The efficacy of propolis extracts as a food supplement in patients with COVID-19. Journal of Experimental and Clinical Medicine, Cilt: 40 Sayı: 3, 443–447. https://ajindex.com/articles/971989

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Rello J, Belliato M, Dimopoulos MA, Giamarellos-Bourboulis EJ, Jaksic V, Martin-Loeches I, et al. Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. Anaesth Crit Care Pain Med. 2020 Dec;39(6):723–30
  2. Docea A, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M, et al. A new threat from an old enemy: Re emergence of coronavirus (Review). Int J Mol Med. 2020 Mar 27
  3. Coronaviridae Study Group. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr 2;5(4):536–44
  4. D’Souza R, Ashraf R, Rowe H, Zipursky J, Clarfield L, Maxwell C, et al. Pregnancy and COVID ‐19: pharmacologic considerations. Ultrasound in Obstetrics & Gynecology. 2021 Feb;57(2):195–203
  5. To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020 May;20(5):565–74
  6. Rijkers G, Murk JL, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al. Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections. J Infect Dis. 2020 Sep 14;222(8):1265–9
  7. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. Journal of Thrombosis and Haemostasis. 2020 May 27;18(5):1023–6
  8. Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clinical Microbiology and Infection. 2020 Sep;26(9):1259.e5-1259.e7
  9. Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021 Jul;80(7):943–51
  10. Sterne JAC, Murthy S, Diaz J V., Slutsky AS, Villar J, Angus DC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. JAMA. 2020 Oct 6;324(13):1330
  11. Kmietowicz Z. Covid-19: Selected NHS patients will be treated with remdesivir. BMJ. 2020 May 26;m2097
  12. Marconi VC, Ramanan A V, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRI